TB-500 (Thymosin Beta-4) is one of the most abundant intracellular peptides in the human body and one of the most studied systemic recovery peptides in contemporary research. Its unique actin-binding mechanism enables broad-spectrum tissue repair activity unmatched by more locally-acting growth factors.
What is TB-500?
TB-500 is the synthetic analogue of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino-acid peptide first isolated from bovine thymus in 1981 by Drs. Low and Goldstein. Tβ4 is the most abundant member of the beta-thymosin family and one of the most abundant intracellular peptides in mammalian cells — found at micromolar concentrations in virtually every tissue.
TB-500 represents the key active fragment of Tβ4 responsible for its biological activity. Unlike recombinant full-length Tβ4, the synthetic TB-500 fragment offers superior bioavailability as an isolated research compound. Tβ4 is also commercially available as the ophthalmic formulation RGN-259 (RegeneRx), which has completed Phase 3 clinical trials for neurotrophic keratopathy.
Known Mechanism of Action
G-Actin Sequestration (Primary Mechanism)
TB-500's primary mechanism is sequestration of G-actin (globular actin). The peptide binds to G-actin with high affinity (Kd ~2 µM) through its conserved actin-binding motif (LKKTETQ). By binding G-actin, TB-500 prevents its polymerisation into F-actin filaments, thereby modulating actin cytoskeletal dynamics. This fundamentally affects cellular processes including migration, differentiation, adhesion, contraction, and survival.
The actin system is the most abundant protein system in eukaryotic cells — TB-500's modulation of this system explains its remarkably broad tissue effects across muscle, tendon, cardiac, neural, and epithelial tissues.
MMP-2 Upregulation and ECM Remodelling
TB-500 upregulates matrix metalloproteinase-2 (MMP-2) expression and activity. MMP-2 is a key collagenase involved in extracellular matrix (ECM) remodelling during tissue repair. This upregulation facilitates the breakdown of damaged ECM components and the deposition of organised new matrix — a process essential for functional tissue restoration.
VEGF and KGF-Mediated Angiogenesis
Research demonstrates TB-500 promotes angiogenesis through upregulation of vascular endothelial growth factor (VEGF) and keratinocyte growth factor (KGF). These growth factors drive endothelial cell proliferation, migration, and tube formation — supporting the establishment of functional microvasculature in repair zones.
Cardiac Protection
In cardiac research, Tβ4 activates the PKCε (protein kinase C epsilon) pathway, which phosphorylates and activates Akt survival signalling. This pathway reduces infarct size and improves myocardial function in preclinical ischaemia-reperfusion models — effects not observed with more conventional growth factor approaches.
Key Research Applications
- Muscle Repair: Rat muscle laceration models demonstrate accelerated functional recovery, reduced fibrosis, increased angiogenesis, and improved myofibre regeneration with TB-500 administration.
- Tendon/Ligament Healing: Rat Achilles tendon transection models show improved tensile strength, collagen organisation (increased Type I/III ratio), and earlier return to function.
- Cardiac Ischaemia: Mouse and rat MI models demonstrate reduced infarct size (30–50% reduction), improved ejection fraction, and enhanced angiogenesis in peri-infarct zones.
- Wound Healing: Full-thickness dermal wound models show accelerated closure, increased granulation tissue formation, and improved scar quality.
- Corneal Repair: Rabbit corneal wound models (alkali burn, PRK) demonstrate accelerated epithelial healing, reduced inflammation, and decreased corneal opacity.
Research Protocols & Dosing
Standard rodent protocols use 2.5–10 mg/kg loading phase (divided over 2–4 days) followed by 0.5–2 mg/kg every 2–3 days for 2–4 weeks. TB-500 is typically administered subcutaneously or intramuscularly. Its systemic distribution enables uniform tissue levels regardless of injection site.
Stability
TB-500 is stable as a lyophilized powder at 2–8°C for 12+ months. Once reconstituted, it remains stable for 7–14 days at 2–8°C. The peptide is water-soluble and reconstitutes readily in bacteriostatic water. Avoid freeze-thaw cycles and protect from light.
This article is provided for scientific and educational purposes only. TB-500 is available exclusively for laboratory research purposes.
Element42 Peptides — Australian owned, third-party tested. View TB-500 product page.